Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero®)

The estimated NNV should be taken into account when deciding policy to recommend Bexsero® for close contacts of single cases in household or educational settings. Bexsero® may have a protective role in clusters and outbreaks.